Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Wegovy is a GLP-1 receptor agonist administered by subcutaneous injection, bypassing the gastrointestinal tract and reducing likelihood of direct interactions with oral probiotics
August 2024
To manage outcomes and costs, one in three (34%) firms now require employees to participate in lifestyle or clinical support programs before allowing clinical approval of GLP-1 agonists for weight loss
GLP-1 drugs (exenatide, liraglutide etc), as well as GIP/GLP-1 hybrid peptides (tirzepatide), are clinically approved for diabetes and/or obesity, with GLP-2 based drugs (teduglutide) approved for the treatment of short bowel syndrome
Promote Other Supportive Lifestyle Measures Ultimately, weight and nutrition are really just two pieces in the larger puzzle of individual health and wellness
